

Jean-Francois Tanguay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7687215/publications.pdf>

Version: 2024-02-01

68
papers

2,885
citations

279487

23
h-index

168136

53
g-index

68
all docs

68
docs citations

68
times ranked

3775
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Artificial Intelligence Applications in Cardiology: Current Landscape, Limitations, and the Road to Real-World Applications. <i>Journal of Cardiovascular Translational Research</i> , 2023, 16, 513-525.	1.1	5
2	The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey. <i>Canadian Journal of Cardiology</i> , 2022, 38, S79-S88.	0.8	6
3	The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease. <i>Cardiovascular Research</i> , 2021, 117, 1776-1789.	1.8	38
4	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	1.6	119
5	Platelet Quiescence in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American Heart Association</i> , 2021, 10, e016602.	1.6	2
6	The FDA and PLATO Investigators death lists: Call for a match. <i>International Journal of Clinical Practice</i> , 2021, 75, e14105.	0.8	2
7	Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada. <i>CJC Open</i> , 2021, 3, 814-821.	0.7	3
8	Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation: Findings from the CONNECT AF+PCI study. <i>CJC Open</i> , 2021, 3, 1419-1427.	0.7	1
9	Infections Deaths in the PLATO Trial. <i>TH Open</i> , 2021, 05, e503-e506.	0.7	1
10	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1298-1307.	0.8	12
11	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 3132-3140.	1.0	52
12	Verifying Death Reports in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Journal of Therapeutics</i> , 2020, 27, e563-e572.	0.5	5
13	Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008603.	1.4	28
14	Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. <i>CJC Open</i> , 2020, 2, 118-128.	0.7	9
15	Clinical outcomes of bioresorbable vascular scaffold to treat all-comer patients. Are patients with acute coronary syndrome better candidates for bioresorbable vascular scaffold?. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 228-234.	0.3	2
16	A web-based tailored nursing intervention (TAVIE en marche) aimed at increasing walking after an acute coronary syndrome: Multicentre randomized trial. <i>Journal of Advanced Nursing</i> , 2019, 75, 2727-2741.	1.5	4
17	Isolating and expanding endothelial progenitor cells from peripheral blood on peptide-functionalized polystyrene surfaces. <i>Biotechnology and Bioengineering</i> , 2019, 116, 2598-2609.	1.7	4
18	Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual) <i>TJ ETQq0 0 0 rgBT/Overlock 10 Tf 50</i>	0.7	4

#	ARTICLE	IF	CITATIONS
19	Right Atrial Mechanisms of Atrial Fibrillation in a Rat Model of Right Heart Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1332-1347.	1.2	72
20	Targeted Temperature Management After Cardiac Arrest: The Montreal Heart Institute Experience. <i>CJC Open</i> , 2019, 1, 238-244.	0.7	0
21	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 576-585.	1.8	8
22	Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 629-638.	1.2	190
23	Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y ₁₂ receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 543-553.	0.4	15
24	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018, 34, 214-233.	0.8	181
25	Longer Inflation Duration and Predilation "Sizing" Postdilation Improve Bioresorbable Scaffold Outcomes in a Long-term All-Corners Canadian Registry. <i>Canadian Journal of Cardiology</i> , 2018, 34, 752-758.	0.8	4
26	Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction. <i>Acta Cardiologica</i> , 2018, 73, 276-281.	0.3	1
27	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	1.6	211
28	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 190-198.	0.7	18
29	Bioresorbable Vascular Scaffold During ST-Elevation Myocardial Infarction: A Systematic Review. <i>Canadian Journal of Cardiology</i> , 2017, 33, 515-524.	0.8	9
30	Percutaneous Coronary Interventions in Patients Requiring Long-Term Oral Anticoagulation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1643-1645.	1.1	0
31	Bioresorbable vascular scaffold to treat in-stent restenosis: Single-center experience. <i>Journal of Interventional Cardiology</i> , 2017, 30, 558-563.	0.5	1
32	Everolimus-eluting bioresorbable vascular scaffold implantation to treat saphenous vein graft disease, single-center initial experience. <i>Journal of Interventional Cardiology</i> , 2017, 30, 433-439.	0.5	3
33	Early Multiple Coronary Micro Aneurysms After Bioresorbable Vascular Scaffold Implantation. <i>Canadian Journal of Cardiology</i> , 2017, 33, 292.e9-292.e11.	0.8	3
34	Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial. <i>Journal of Thoracic Disease</i> , 2017, 9, E440-E443.	0.6	2
35	Evaluation of a Web-Based Tailored Nursing Intervention (TAVIE en marche) Aimed at Increasing Walking After an Acute Coronary Syndrome: A Multicenter Randomized Controlled Trial Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e64.	0.5	3
36	A Web-Based Tailored Intervention to Support Illness Management in Patients With an Acute Coronary Syndrome: Pilot Study. <i>JMIR Cardio</i> , 2017, 1, e4.	0.7	1

#	ARTICLE	IF	CITATIONS
37	Immediate Versus Delayed Invasive Intervention for Non-“ST-Segment Elevation Myocardial Infarction Patients (RIDDLE-NSTEMI Study). <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1415-1416.	1.1	0
38	Prognostic impact of the residual <sc>SYNTAX</sc> score on in-hospital outcomes in patients undergoing primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 740-747.	0.7	22
39	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 2094-2098.	1.6	19
40	Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 133, 1772-1782.	1.6	47
41	Platelet function testing as a biomarker for efficacy of antiplatelet drugs. <i>Biomarkers in Medicine</i> , 2016, 10, 903-918.	0.6	8
42	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	83
43	Evaluation of a Web-Based E-Learning Platform for Brief Motivational Interviewing by Nurses in Cardiovascular Care: A Pilot Study. <i>Journal of Medical Internet Research</i> , 2016, 18, e224.	2.1	37
44	Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. <i>Heart</i> , 2015, 101, 1219-1224.	1.2	15
45	Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2211-2221.	1.2	240
46	Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1552-1562.	1.1	51
47	Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1725-1731.	0.8	26
48	Microwave-assisted synthesis of surface-enhanced Raman scattering nanoprobes for cellular sensing. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 122, 617-622.	2.5	8
49	2-Dioleoyl-sn-glycero-3-phosphocholine-based nanoliposomes as an effective delivery platform for 17 β -estradiol. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 369-375.	2.0	11
50	Transapical Mitral Implantation of the Tiara Bioprosthesis. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 154-162.	1.1	39
51	Abstract 13993: Impact of Prasugrel Pretreatment and Timing of Coronary Artery Bypass Grafting on Clinical Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction: From the Ac Coast Study. <i>Circulation</i> , 2014, 130, .	1.6	1
52	Estradiol inhibits vascular endothelial cells pro-inflammatory activation induced by C-reactive protein. <i>Molecular and Cellular Biochemistry</i> , 2013, 373, 137-147.	1.4	27
53	Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1334-1345.	0.8	97
54	Antiplatelet Therapy in Acute Coronary Syndrome and Atrial Fibrillation: Aspirin. <i>Advances in Cardiology</i> , 2012, 47, 20-30.	2.6	2

#	ARTICLE	IF	CITATIONS
55	Key Fatty Acid Combinations Define Vascular Smooth Muscle Cell Proliferation and Viability. <i>Lipids</i> , 2012, 47, 1073-1084.	0.7	6
56	A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with nonâ€“ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study. <i>American Heart Journal</i> , 2011, 161, 650-656.e1.	1.2	23
57	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2011, 27, S1-S59.	0.8	106
58	Nature of fatty acids in high fat diets differentially delineates obesity-linked metabolic syndrome components in male and female C57BL/6J mice. <i>Diabetology and Metabolic Syndrome</i> , 2011, 3, 34.	1.2	47
59	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010, 376, 1233-1243.	6.3	725
60	Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 939-953.	0.6	1
61	A cardiovascular monitoring system used in conscious cynomolgus monkeys for regulatory safety pharmacology: Part 2: Pharmacological validation. <i>Journal of Pharmacological and Toxicological Methods</i> , 2007, 56, 122-130.	0.3	27
62	Local delivery of 17Î²-estradiol improves reendothelialization and decreases inflammation after coronary stenting in a porcine model. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1042-1047.	1.8	21
63	Vascular healing after stenting: the role of 17-beta-estradiol in improving re-endothelialization and reducing restenosis. <i>Canadian Journal of Cardiology</i> , 2005, 21, 1025-30.	0.8	7
64	Estrogen Regulation of Endothelial and Smooth Muscle Cell Migration and Proliferation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1585-1590.	1.1	110
65	Coronary artery endothelial protection after local delivery of 17Î²-estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1570-1576.	1.2	50
66	Late (> 48 hr) myocardial infarction after PTCA: Clinical and angiographic characteristics of infarction related or not to the angioplasty site. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 53, 155-162.	0.7	1
67	Repair of left anterior descending coronary artery perforation by magic wallstent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 48, 304-307.	0.7	9
68	Dual Antiplatelet Therapy after PCI: When Could We Go Shorter?. , 0, , .		0